Author:
Lee Oh-Hyun,Kim Yongcheol,Son Nak-Hoon,Cho Deok-Kyu,Kim Jung-Sun,Kim Byeong-Keuk,Choi Donghoon,Hong Myeong-Ki,Jeong Myung Ho,Jang Yangsoo
Abstract
BackgroundIn patients with ST-elevation myocardial infarction (STEMI) with a high risk of ischemic events, the safety and efficacy of drug-eluting stent (DES) are unclear.MethodsBased on the nationwide, multicenter, prospective registry, we selected 1,592 patients who underwent primary percutaneous coronary intervention (PCI) with everolimus-(EES) and zotarolimus-eluting stent (ZES) for STEMI with a high risk of an ischemic event. The occurrence of target lesion failure (TLF) for 3 years, defined as the composite of cardiac death, target vessel myocardial infarction (TV-MI), and ischemia-driven target lesion revascularization (ID-TLR), was evaluated.ResultsThe prevalence of high ischemic risk features was observed in 43.4% (2,744/6,325) of overall patients with STEMI. Among them, a total of 1,078 and 514 patients were treated with EES and ZES, respectively. At 3 years, the risk of TLF was not significantly different between the two groups (p = 0.93). In addition, the incidence of cardiac death, TV-MI, ID-TLR, and definite/probable stent thrombosis (ST) were also not different between the two groups. Moreover, elderly patients (age > 75 years) and PCI for the left main disease were identified as independent predictors of TLF.ConclusionImplantation of EES or ZES provided comparable clinical outcomes in STEMI patients and high ischemic risks.
Funder
Yonsei University College of Medicine
Korea Centers for Disease Control and Prevention
Subject
Cardiology and Cardiovascular Medicine